Immuno-therapy is an emphasized trend for oncology treatment. There are two major ways of engaging the immune cells to the tumor cells: CAR-T and bispecific antibodies. By genetic engineering of the T cells by integrating the tumor antigens, the CAR-T cells can recognize specifically the tumor cells. However, there are some limitations on CAR-T application: hard to manufacture, risk of cytokine storm, and so far only proven to be effective for blood tumors. Bispecific antibodies, such as the approved Blincyte, stability, immunogenecity, half-life and manufacturing are major issues.

 

Gmax has developed Bi-Body (Bi-specific T cells engaging Antibody) platform to overcome the current problems facing by CAR-T and bispecific antibodies. The Bi-Body is a modular structure, designed to engage T cells with tumor cells and thus kill them. The Ag-recognizing Ab module can be genetically replaced with a new Ab for a new target. The molecule is stable, easy to manufacture, low immunogenicity. Several Bi-Bodies for various cancer types, both blood and solid tumors, are under development.